Peptide■America

Evidence review

Epitalon and the Lifespan Claims

Does the evidence support the lifespan and telomerase claims made for Epitalon?

The answer

No. The telomerase finding is a 2003 cell-culture report; the nine trial-type human records belong almost entirely to epithalamin, a glandular extract, appear in Russian journals or their translated editions, and the most recent was published in 2011.

Molecules
Epitalon
US status
PCAC-recommended · pending
Sources
12
Reviewed
September 2026
The human trial record, by which name was searched

Eight of the nine trial-type records study epithalamin, the glandular extract; the one naming the tetrapeptide is a retinal study.

By Diane Walker · Reference Editor

What is the claim, and what is it standing on?

Epitalon is sold on two related promises: that it lengthens telomeres, and that it extends life. The first rests on a single 2003 report in which the tetrapeptide induced telomerase activity and telomere elongation in cultured human fetal fibroblasts [1]. That is a dish, not a person, and the paper came from the St. Petersburg institute that designed the peptide; a 2025 review collects what has and has not been replicated since [2].

The reach of the telomere claim in the literature is measurable. Searched in September 2026, the two tetrapeptide names combined with telomere terms return 10 indexed records, 6 of which carry the Humans subject heading and none of which carries either trial publication type [3]. Six human-tagged records is the whole telomere file, and a human-tagged record is not a person who was dosed and followed; the monograph records the regulatory position; the evidence is counted below.

How many human trials of Epitalon exist?

Nine, on the most generous search, and one on the strict one. Across four names — the tetrapeptide as Epitalon or Epithalon, the parent extract epithalamin, and the sequence Ala-Glu-Asp-Gly — PubMed returns 215 indexed records, 79 tagged Humans, 9 under the clinical-trial publication type and 6 under the randomized type [3]. The tetrapeptide names alone return 114 records, 35 tagged Humans, 1 under the clinical-trial type and 0 under the randomized type [3].

A filter that has stopped matching returns zero for every substance in the database, so the same session put a control term with a large trial literature through the identical filters, and the reference records those counts beside the tetrapeptide's one [3].

Each of the nine records was read. Eight study epithalamin or an unnamed pineal-gland peptide preparation, in cervical cancer in 1979 and 1999, craniocerebral trauma in 2004, melatonin rhythm in 2004, arterial pressure in 2008, and the geroprotective series of 2003, 2006 and 2011; six of the nine are Russian-language publications, and every one appears in a Russian journal or its translated edition or carries the designing institute's authors [3]. The trial record prints the same nine beside every other count in the index.

What do the epithalamin studies report, and why do they not transfer?

The lifespan claim traces to three papers that share an author. A 2011 report followed 39 coronary patients given six courses of epithalamin over three years against 40 patients on basic therapy alone, and reported lower mortality over a 15-year follow-up [5]. A 2006 report from the same authors described a 12-year randomized study in elderly coronary patients in which deaths in the treated group were 28% fewer than in the control group [6]. A 2003 report assessed thymalin and epithalamin in 266 elderly and older persons over six to eight years and reported mortality 1.6- to 1.8-fold lower in the epithalamin group than in the control [7].

Those are the strongest numbers in the file, and none of them concerns the compound in the vial. Epithalamin is a crude extract of pineal gland; Epitalon is a four-amino-acid synthetic designed later as a defined stand-in for it. A mortality figure measured on the extract is a fact about the extract. The abstracts do not describe blinding or placebo, the comparisons are against basic therapy, and the three reports share authors; none of that is disqualifying, and all of it is what a reader would want to know before the word randomized is allowed to carry the claim.

What is the one trial that names the tetrapeptide?

It is a 2002 report in retinitis pigmentosa. Its abstract describes work in Campbell rats and in patients with degenerative retinal lesions, states a positive clinical effect in 90% of cases, and gives no denominator, no comparison group and no endpoint definition [4]. PubMed tags it as a controlled clinical trial, which is why it is counted here; nothing about it concerns aging, telomeres or lifespan.

That is the entire controlled human record of the marketed molecule for any endpoint. Under the stricter randomized-controlled-trial type the tetrapeptide returns nothing at all [3]. The honest statement is therefore not that Epitalon has failed a lifespan trial; it is that no such trial has been run, and the extrapolation from a fibroblast culture and a glandular extract to a longevity product is being made by the seller, not by the literature.

Where does that leave the regulatory position?

Epitalon left Category 2 of the interim 503A bulks list in April 2026 without Category 1 listing, and in July 2026 the Pharmacy Compounding Advisory Committee voted to recommend adding it to the section 503A list. The margin is reported as 7–4 with one abstention by McDermott Will & Schulte and by LumaLex Law, whose separate accounts agree substance by substance [8, 9]; the FDA has published no minutes, transcript or vote summary, so the figure is secondary and this page says so where it prints it. The vote ledger carries the sourcing for the whole meeting.

The FDA's own safety entry for the substance, still published among substances nominated but withdrawn, states that the agency has not identified safety-related information for the proposed route of administration and lacks sufficient information to know whether the drug would cause harm if administered to humans [10]. The substance appears in no category of the bulks list published on May 14, 2026 [11], and Drugs@FDA holds no application under either spelling of the name, while the same query returned an approved application for a control term in the same run [12]. The vote is advisory; the pending page explains what it changes, which is nothing yet, and material sold under the name is research-use-only supply outside pharmacy oversight.

Elsewhere in this index

Monographs

Topics

Reference tables

Sources

Every source below is inherited from a monograph in this index; this review introduces none of its own. The pointer beside each entry names the monograph and the reference number it came from.

  1. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590–592. PMID 12937682 Verified August 2026 on the epitalon monograph, reference 1.
  2. Araj SK, et al. Overview of Epitalon — highly bioactive pineal tetrapeptide with promising properties. Int J Mol Sci. 2025;26(6). PMID 40141333 Verified August 2026 on the epitalon monograph, reference 2.
  3. PubMed, National Library of Medicine. Census run 2026-09-01 across four name variants — "Epitalon" OR "Epithalon" OR "epithalamin" OR "Ala-Glu-Asp-Gly" — returning 215 indexed records, 79 carrying the Humans MeSH term, 9 under "clinical trial"[Publication Type] and 6 under "randomized controlled trial"[Publication Type]; 106 of the 215 are Russian-language records and 6 of the 9 trial-type records are Russian-language. The two tetrapeptide names alone — "Epitalon" OR "Epithalon" — return 114 records, 35 tagged Humans, 1 under the clinical-trial type and 0 under the randomized type; the tetrapeptide names combined with telomer* return 10 records, 6 tagged Humans, none of either trial type. All nine trial-type records were opened and read: one names the tetrapeptide (a 2002 retinitis pigmentosa report); the other eight study epithalamin or an unnamed pineal-gland peptide preparation, in cervical cancer (1979, 1999), craniocerebral trauma (2004), melatonin rhythm (2004), arterial pressure (2008) and the geroprotective series of 2003, 2006 and 2011. Every one appears in a Russian journal or its translated edition, or carries the designing institute's authors. The publication-type filter was proved live in the same run against a control term returning 8,906 records under the clinical-trial type and 6,115 under the randomized type; the invalid tag clinicaltrial[pt] returned 0 for that control term, and a deliberately invalid record identifier errored at the start and the end of the run. The counts reproduce the 2026-08-31 run behind the trial-record table exactly. Source Verified September 2026 on the epitalon monograph, reference 5.
  4. Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett. 2002;23(4):365–368. PMID 12195242 Verified September 2026 on the epitalon monograph, reference 9.
  5. Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med. 2011;151(3):366–369. PMID 22451889 Verified September 2026 on the epitalon monograph, reference 6.
  6. Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bull Exp Biol Med. 2006;142(3):356–359. PMID 17426848 Verified September 2026 on the epitalon monograph, reference 7.
  7. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233–240. PMID 14523363 Verified September 2026 on the epitalon monograph, reference 8.
  8. McDermott Will & Schulte. Bulk-list bound? PCAC backs majority of peptides in two-day public meeting. July 27, 2026. Read 2026-08-31. A secondary account, cited because the FDA has published no minutes, transcript or vote summary for the July 23–24, 2026 meeting; the agency's meeting page, content current as of August 6, 2026 and re-read on 2026-08-31, carries the briefing documents, the final agenda, the final meeting roster and the FDA presentations, and no record of any vote. Its vote table gives Epitalon (free base / acetate), on Friday, July 24, as "7 – 4 (1 abstention)", recommended for inclusion. Source Verified August 2026 on the epitalon monograph, reference 3.
  9. LumaLex Law. The July 2026 PCAC Peptide Meeting. July 25, 2026. Read 2026-08-31. A second, independent secondary account, checked against the first: it prints all seven July 23–24, 2026 votes as a table — BPC-157, KPV and TB-500 at 8–6–1, MOTS-c at 7–5–2, Semax at 8–5–1, Epitalon at 7–4–1, and emideltide (DSIP) at 6–7–1 — and the two accounts agree substance by substance. Source Verified August 2026 on the epitalon monograph, reference 4.
  10. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, content current as of April 22, 2026, table of bulk drug substances nominated but withdrawn, entry for Epitalon. Read 2026-09-01. The entry states that compounded drugs containing epitalon may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities, that FDA has not identified safety-related information regarding epitalon for the proposed route of administration, and that the agency therefore lacks sufficient information to know whether the drug would cause harm if administered to humans. Source Verified September 2026 on the epitalon monograph, reference 10.
  11. US Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, updated May 14, 2026. Read in full 2026-09-01: neither "Epitalon" nor "Epithalon" occurs anywhere in the document, so the substance appears in none of Category 1, Category 2, or Category 3. Control in the same read: the same document names GHK-Cu six times. Source Verified September 2026 on the epitalon monograph, reference 11.
  12. US Food and Drug Administration, Drugs@FDA through the openFDA drugsfda endpoint. Queried 2026-09-01 on the generic name, the substance name and the brand name for "epitalon" and "epithalon": no matching application. Control in the same run: the identical query for "bremelanotide" returned NDA 210557. Source Verified September 2026 on the epitalon monograph, reference 12.